New diagnostic modalities in the diagnosis of heart failure

Journal of the National Medical Association

Volumn 96, Issue 11, 2004, Pages 1424-1430

  Mitchell, Judith E ^a,b   Palta, Sanjeev ^b  

^a Heart Failure Center   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

B type natriuretic peptide; BioZ; Diagnosis; Heart failure; Impedance cardiography

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ARTICLE; DIAGNOSTIC ACCURACY; HEART FAILURE; HEMODYNAMICS; HOSPITAL COST; HOSPITAL PATIENT; HUMAN; IMPEDANCE CARDIOGRAPHY; INTERMETHOD COMPARISON; OUTPATIENT; PRIORITY JOURNAL; PROTEIN DETERMINATION;

ALGORITHMS; CARDIOGRAPHY, IMPEDANCE; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PRACTICE GUIDELINES;

EID: 8344260649     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Kupari M, Lindroos M, Livanainen AM, et al. Congestive heart failure in old age: prevalence, mechanisms, and four-year prognosis in the Helsinki Aging Study. J Intern Med. 1997;241:387-394.
2. U.S. Department of Health and Human Services: NHLBI, congestive heart failure data fact sheet, 1996. http://www.nhlbi.nih.gov/health/public/ heart/other/chf.htm.
3. Dries DL, Exner DV, Gersh BJ, et al. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med. 1999;340:609-616.
4. Remmes J, Miettinen H, Reunanen A, et al. Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J. 1991;12:315-21.
5. Wheeldon NM, MacDonald TM, Flucker CJ, et al. Echocardiography in chronic heart failure in the community. Q J Med. 1993;86:17-23.
6. Pfeifer MA, Braunwald E, Moye LA, et al. Effects of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;32:669-685.
7. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. The SOLVD Investigators. N Engl J Med. 1992;327:685-691.
8. Hunt, et al. ACC/AHA Guidelines: Evaluation and Management of Chronic Heart Failure in the Adult. http://www.acc.org/clinical/guidelines/failure/ hf_index.htm.
9. Massie BM, Shah NB. Evolving trends in the epidemiological factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J. 1997;133:703-712.
10. Hunt, et al. ACC/AHA Guidelines: Evaluation and Management of Chronic Heart Failure in the Adult. http://www.acc.org/clinical/guidelines/failure/ hf_index.htm.
11. Heart Failure Society of America 2001. www.hfsa.org.
12. Strobeck M, Silver M, Ventura H. Impedance Cardiography: Noninvasive Measurement of Cardiac Stroke Volume and Thoracic Fluid Content. Congest Heart Fail. 2000;6:3-6.
13. Sageman WS, Riffenburgh RH, Spiess BD. Equivalence of bioimpedance and thermodilution in measuring cardiac index after cardiac surgery. J Cardiothorac Vasc Anesth. 2002; 16:8-14.
14. Drazner M, Thompson B, Rosenberg P, et al. Comparison of impedance cardiography with invasive hemodynamic measurements in patients with heart failure secondary to ischemic or nonischemic cardiomyopathy. Am J Cardiol. 2002;89:993-995.
15. Van De Water JM, Miller TW. Impedance cardiography: the next vital sign technology? Chest. 2003;123:2028-2033.
16. Albert N, Hail M, Li J, et al. Equivalence of bioimpedance and TD in measuring CO/CI in patients with advanced, decompensated chronic heart failure hospitalized in critical care. J Am Coll Cardiol. 2003;41(6 suppl):211A.
17. Shah MR, O'Connor CM, Sopko G, et al. Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE): Design and Rationale. Am Heart J. 2001;141:528-535.
18. Hendrickson K. Cost-effectiveness of noninvasive hemodynamic monitoring . AACN Clinical Issues. 1999;10:419-426.
19. Silver M, Cianci P, Brennan S, et al. Evaluation of impedance cardiography as an alternative to pulmonary artery catheterization in critically ill patients. Congest Heart Fail. 2004;10(2 suppl 2):17-21.
20. Yancy C, Abraham W. Noninvasive hemodynamic monitoring in heart failure: utilization of impedance cardiography. Congest Heart Fail. 2003;9: 241-250.
21. Strobeck M, Silver M, Ventura H. Impedance Cardiography: Noninvasive Measurement of Cardiac Stroke Volume and Thoracic Fluid Content. Congest Heart Fail. 2000;6:3-6.
22. Burnett JC. Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertension. 1999;17(suppl 1):S37.
23. Maisel A. Algorithms for Using B-Type Natriuretic Peptide Levels in the Diagnosis and Management of Congestive Heart Failure. Critical Pathways in Cardiology. Vol. 1 No. 2. June 2002.
24. Maisel A. Algorithms for Using B-Type Natriuretic Peptide Levels in the Diagnosis and Management of Congestive Heart Failure. Critical Pathways in Cardiology. Vol. 1 No. 2. June 2002.
25. Packer M, Cohn JN. Consensus Recommendations for the Management of Chronic Heart Failure. Am J Cardio. 1999;Vol.83 (2A).
26. Maisel A, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J. 2001;141:367-374.
27. Maisel A, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J. 2001;141:367-374.
28. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid Measurement of B-type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure. N Engl J Med. 2002;347.
29. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid Measurement of B-type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure. N Engl J Med. 2002;347.
30. Beyond Four Walls: Cost-Effective Management of Chronic Congestive Heart Failure. The Advisory Board Company. 1994. pg. 179.
31. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid Measurement of B-type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure. N Engl J Med. 2002;347.
32. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent care setting. JACC. 2001;37:379-385.
33. Davis M, Espiner E, Richards G, et al. Plasma Brain Natriuretic Peptide in Assessment of Acute Dyspnea. Lancet. 1994;343:440-444.
34. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent care setting. JACC. 2001;37:379-385.
35. Morrison LK, Harrison A, Krishnaswamy P, et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. JACC. 2002;39:202-209.
36. Pfeifer MA, Braunwald E, Moye LA, et al. Effects of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;32:669-685.
37. Kazanegra R, Cheng V, Garcia A, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Cardiac Failure. 2001;1:21-29.
38. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid Measurement of B-type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure. N Engl J Med. 2002;3.
39. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of Compensation of Endogenous Cardiac Natriuretic Peptide System in Chronic Heart Failure. Circulation. 1997;96:509-516.
40. Maisel AS. Algorithms for Using B-Type Natriuretic Peptide Levels in the Diagnosis and Management of Congestive Heart Failure. Critical Pathways in Cardiology. 2002;2.
41. Maisel AS. Algorithms for Using B-Type Natriuretic Peptide Levels in the Diagnosis and Management of Congestive Heart Failure. Critical Pathways in Cardiology. 2002;2.